The response to ACTH is determined early in the treatment of infantile spasms
- PMID: 25644547
- DOI: 10.1684/epd.2014.0723
The response to ACTH is determined early in the treatment of infantile spasms
Abstract
Although adrenocorticotropic hormone is the most commonly used treatment for infantile spasms in the United States, the optimal regimen for this indication is not known. The purpose of this study was to elucidate the optimal adrenocorticotropic hormone treatment duration. We conducted a retrospective chart review of response to adrenocorticotropic hormone among all patients with infantile spasms managed at our institution from January 2009 to September 2013. Treatment response was defined as clinical remission for greater than or equal to 28 days starting at any point within the adrenocorticotropic hormone course and remission of hypsarrhythmia (or definite EEG improvement if hypsarrhythmia was absent at baseline). For responders, the diagnostic and post-treatment EEG tracings were reviewed. Electroclinical remission was achieved in 21 of 39 patients (54%) receiving adrenocorticotropic hormone, including 11/25 (44%) receiving a long course (typically 12 weeks) and 10/14 (71%) receiving a short course (typically four weeks). The mean time to clinical remission was 5.8 days (median: 5 days; range: 1-20 days). Only one patient responded beyond two weeks of treatment. This study provides Class IV evidence that among patients with infantile spasms, the response to adrenocorticotropic hormone is most often determined early in the treatment course. Given the importance of rapid remission, clinicians should consider adding or changing treatment if infantile spasms do not resolve within two weeks of adrenocorticotropic hormone initiation. Further study is needed to determine the optimal adrenocorticotropic hormone regimen for infantile spasms.
Keywords: ACTH; West syndrome; adrenocorticotropic hormone; infantile spasms.
Similar articles
-
Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms.Neurology. 2022 Nov 29;99(22):e2494-e2503. doi: 10.1212/WNL.0000000000201232. Epub 2022 Aug 29. Neurology. 2022. PMID: 36038267 Free PMC article.
-
Infantile Spasms Respond Poorly to Topiramate.Pediatr Neurol. 2015 Aug;53(2):130-4. doi: 10.1016/j.pediatrneurol.2015.05.003. Epub 2015 May 9. Pediatr Neurol. 2015. PMID: 26068002
-
Spontaneous remission of infantile spasms and hypsarrhythmia following acute infection with high-grade fever.Epilepsy Res. 2007 Dec;77(2-3):102-7. doi: 10.1016/j.eplepsyres.2007.09.003. Epub 2007 Oct 26. Epilepsy Res. 2007. PMID: 17964758
-
Adrenocorticotropic hormone for the treatment of West Syndrome in children.Ann Pharmacother. 2013 May;47(5):744-54. doi: 10.1345/aph.1R535. Epub 2013 Apr 19. Ann Pharmacother. 2013. PMID: 23606552 Review.
-
[Infantile spasms and West syndrome].Rev Med Chir Soc Med Nat Iasi. 2004 Jan-Mar;108(1):40-5. Rev Med Chir Soc Med Nat Iasi. 2004. PMID: 15688754 Review. Romanian.
Cited by
-
Brazilian experts' consensus on the treatment of infantile epileptic spasm syndrome in infants.Arq Neuropsiquiatr. 2023 Sep;81(9):844-856. doi: 10.1055/s-0043-1772835. Epub 2023 Oct 4. Arq Neuropsiquiatr. 2023. PMID: 37793406 Free PMC article.
-
Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms.Neurology. 2022 Nov 29;99(22):e2494-e2503. doi: 10.1212/WNL.0000000000201232. Epub 2022 Aug 29. Neurology. 2022. PMID: 36038267 Free PMC article.
-
Compliance With Standard Therapies and Remission Rates After Implementation of an Infantile Spasms Management Guideline.Pediatr Neurol. 2020 Mar;104:23-29. doi: 10.1016/j.pediatrneurol.2019.11.016. Epub 2019 Dec 3. Pediatr Neurol. 2020. PMID: 31911027 Free PMC article.
-
Management of Infantile Spasms During the COVID-19 Pandemic.J Child Neurol. 2020 Oct;35(12):828-834. doi: 10.1177/0883073820933739. Epub 2020 Jun 23. J Child Neurol. 2020. PMID: 32576057 Free PMC article.
-
West Syndrome: A Review and Guide for Paediatricians.Clin Drug Investig. 2018 Feb;38(2):113-124. doi: 10.1007/s40261-017-0595-z. Clin Drug Investig. 2018. PMID: 29086890 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources